Hrubisko M, Ujházy V
Cancer Research Institute, Slovak Academy of Sciences, Bratislava, Czechoslovakia.
Neoplasma. 1990;37(6):631-8.
Resistance to cisplatin (DDP) and/or iproplatin (CHIP) was induced in vitro in murine L1210 leukemia cells. Double-resistant sublines with combined resistance to both drugs were also developed. Cross resistance investigations with DDP, CHIP, oxoplatinum (OXO), carboplatin (CBDCA) and its quadrivalent derivative OXOCBDCA were performed in these resistant sublines. Lack of cross resistance between DDP and CHIP was found. A higher resistance to CHIP in the double-resistant sublines was observed. A multistep process in the development of resistance to this compound is supposed. The importance of the aminoligand and the role of different pharmacokinetics in the cross resistance are discussed.
在小鼠L1210白血病细胞中体外诱导出对顺铂（DDP）和/或异丙铂（CHIP）的耐药性。还培育出了对两种药物均具有联合耐药性的双耐药亚系。在这些耐药亚系中进行了与DDP、CHIP、奥沙铂（OXO）、卡铂（CBDCA）及其四价衍生物OXOCBDCA的交叉耐药性研究。发现DDP和CHIP之间不存在交叉耐药性。在双耐药亚系中观察到对CHIP的耐药性更高。推测对该化合物耐药性的产生是一个多步骤过程。讨论了氨基配体的重要性以及不同药代动力学在交叉耐药中的作用。
